Kymera Therapeutics (KYMR) Q2 FY26 earnings call

Kymera Therapeutics reported strong Q2 FY26 results, highlighted by the accelerated enrollment completion of its lead KT-621 Phase 2b AD trial, now anticipating earlier data readout and Phase III initiation. The company continues to advance its pipeline, including the KT-579 IRF5 degrader and partnered programs, while maintaining a robust financial position with a cash runway extending into 2029. This quarter underscores Kymera's commitment to translating targeted protein degradation science into transformative oral medicines for immunology.